PMI IPO 2025 Picard Medical, Inc. (PMI) has officially filed for its Initial Public Offering (IPO) on the NYSE American Exchange under the proposed ticker symbol PMI. Through this offering, the company aims to raise approximately $21.99 million by selling 4,250,000 shares at an expected price range of $3.50 to $4.50 per share. With its cutting-edge medical technology subsidiary SynCardia Systems, LLC, PMI is positioning itself as a pioneering force in artificial heart technology.

PMI IPO 2025 Company Overview

Founded as a Delaware holding company, Picard Medical owns 100% of SynCardia Systems, a medical technology company known for manufacturing and selling the only FDA- and Health Canada-approved total artificial heart (SynCardia TAH).

Headquarters: 1992 E. Silverlake Rd., Tucson, AZ
Employees: 75 (as of August 2025)
CEO: Patrick NJ Schnegelsberg
Website: www.syncardia.com

Business Focus

Current Offering: The SynCardia TAH has been implanted in over 2,100 patients across 27 countries, serving as a bridge to transplantation (BTT) for patients with biventricular failure.
Future Vision: Development of the world’s first fully implantable artificial heart as a long-term alternative to heart transplantation.
Upcoming Innovations: Expanding indications from Bridge to Transplantation (BTT) to Bridge to Candidacy (BTC), and eventually supporting patients for two years or longer.

PMI IPO 2025 Details

Proposed Symbol: PMI
Exchange: NYSE American
Price Range: $3.50 – $4.50 per share
Shares Offered: 4,250,000
Over-Allotment Option: 637,500 shares
Offer Amount: $21,993,750
Shares Outstanding (Post-IPO): 72,324,145
Lock-Up Period: 180 days

Underwriters:

Sentinel Brokers Company, Inc.
The Benchmark Company, LLC
Uphorizon, LLC
WestPark Capital, Inc.

Legal & Advisory Teams:

Auditor: MaloneBailey, LLP
Company Counsel: Winston & Strawn LLP
Underwriter Counsel: Sheppard, Mullin, Richter & Hampton LLP
Transfer Agent: Continental Stock Transfer & Trust Company

Financial Performance

As of its latest filing (August 6, 2025), Picard Medical reported:

Revenue: $620,000
Net Income (Loss): –$5.56 million
Total Assets: $11.96 million
Total Liabilities: $40.62 million
Stockholders’ Equity: –$48.92 million

➡️ While the company currently operates at a net loss and carries negative equity, it is betting on future growth opportunities in the life-saving artificial heart technology market.

Market Opportunity

The global artificial heart and ventricular assist device market is expanding due to the rise in end-stage heart failure cases. Heart transplants remain limited due to donor shortages, and technologies like the SynCardia TAH provide a critical bridge to transplantation or candidacy.

PMI’s ambition to create the world’s first fully implantable artificial heart could disrupt the medical device landscape and potentially transform the treatment of heart failure.

Key Risks

Financial Risk: Ongoing losses and high liabilities raise concerns about profitability.
Regulatory Risk: Medical devices require extensive FDA approvals, which may delay product expansion.
Market Adoption: Competition from other cardiac device makers could limit market share.

PMI IPO 2025

PMI IPO 2025 Picard Medical, Inc. (PMI) is a high-risk, high-reward IPO. With its proven SynCardia TAH technology and a clear roadmap toward fully implantable artificial hearts, PMI is positioned at the forefront of cardiovascular innovation. However, investors should weigh the company’s financial losses, heavy liabilities, and regulatory challenges before participating in this offering.

PMI IPO 2025 FAQ

1. What is Picard Medical, Inc. (PMI)?

Picard Medical, Inc. is a Delaware-based holding company that owns SynCardia Systems, LLC, a medical technology firm specializing in artificial heart solutions.

2. What does SynCardia Systems do?

SynCardia manufactures and sells the only FDA- and Health Canada-approved total artificial heart (TAH), used as a bridge to transplantation for patients with severe biventricular heart failure.

3. What is the ticker symbol for Picard Medical’s IPO?

The proposed ticker symbol is PMI, and it will trade on the NYSE American Exchange.

4. What is the price range of the PMI IPO?

The IPO is priced between $3.50 and $4.50 per share.

5. How many shares is PMI offering in its IPO?

Picard Medical is offering 4,250,000 shares, with an additional 637,500 shares available for over-allotment.

6. How much does Picard Medical plan to raise through the IPO?

The company expects to raise approximately $21.99 million.

7. When will the PMI IPO take place?

As of now, the IPO filing has been submitted and is awaiting final approval. The exact date will be announced once confirmed by the SEC and NYSE.

8. Who are the underwriters for the PMI IPO?

The IPO is led by Sentinel Brokers, The Benchmark Company, Uphorizon, and WestPark Capital.

9. How is Picard Medical performing financially?

For its most recent filing, Picard Medical reported:

Revenue: $620,000
Net Loss: –$5.56 million
Total Assets: $11.96 million
Total Liabilities: $40.62 million

10. Does Picard Medical have FDA approval for its products?

Yes. Its artificial heart, the SynCardia TAH, is FDA- and Health Canada-approved for use as a bridge to transplantation.

11. What is the company’s long-term vision?

Picard Medical aims to develop the world’s first fully implantable total artificial heart as a long-term alternative to heart transplantation.

12. How many artificial hearts has SynCardia implanted so far?

To date, over 2,100 SynCardia TAHs have been implanted in patients across 27 countries.

13. What is the lock-up period for PMI IPO?

The lock-up period is 180 days, meaning insiders cannot sell their shares during this time.

14. What are the key risks of investing in PMI IPO?

Some risks include:

Ongoing financial losses
High liabilities
Regulatory hurdles for new medical devices
Competition in the cardiac device industry

15. Is PMI IPO a good investment?

PMI represents a high-risk, high-reward opportunity. Investors who believe in the future of artificial heart technology may find it promising, but risks related to financial performance and regulation must be considered.

If successful, the PMI IPO 2025 could mark a major step forward in the evolution of life-saving artificial heart technology.

PMI IPO 2025: Picard Medical, Inc.Artificial Heart Innovator Targets $22 Million NYSE Listing